OncoTargets and Therapy
Volume 11, 2018 - Issue
Open access
321
Views
71
CrossRef citations to date
0
Altmetric
Review
PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
David D Stenehjem1 Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota;2 Masonic Cancer Center, University of Minnesota, [email protected]
, Dao Tran1 Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota
, Michael A Nkrumah1 Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota
& Shilpa Gupta2 Masonic Cancer Center, University of Minnesota, [email protected];3 Division of Hematology, Oncology and Transplantation, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA, [email protected]Correspondence[email protected]
Pages 5973-5989
|
Published online: 19 Sep 2018
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.